Utilizing Real-World Data and Algorithmic Analyses to Assess Post-Market Clinical Outcomes in Patients Switching Amongst Therapeutically Equivalent Complex Generic Drug Products and Reference Listed Drugs (U01) Clinical Trial Not Allowed
Forecast: not open for applications yet. Dates are the funder's estimate. Save a search and Brieflist marks it when it opens (Grants Pro e-mails you), or get the free weekly digest:
This is a forecast: the funder has announced the grant but applications are not open yet. Dates may change.
Complex generic drug products represent an increasing share of the generic marketplace and may have distinct user interface differences compared to reference listed drug (RLD) products.
Read the official page on Grants.gov ↗ Get new grants like this
- Funder
- Food and Drug Administration (Department of Health and Human Services)
- Where
- 🇺🇸 United States
- Status
- Forecast
- Funding
- Up to $300k per award
- Expected awards
- 1
- Who can apply
- Most organisations
- Topics
- Agriculture & food Justice & security
- Opportunity number
- FOR-FD-24-003
- Instrument
- Cooperative agreement
About this grant
Complex generic drug products represent an increasing share of the generic marketplace and may have distinct user interface differences compared to reference listed drug (RLD) products. A modernized post-market surveillance approach is needed to compare clinical outcomes between complex generic products and their corresponding RLD products to monitor for potential issues with therapeutic equivalence and to inform regulatory decision making. Real-world data (RWD) combined with machine learning (ML) and/or artificial intelligence (AI) could help to identify post-market signals efficiently in an automated and repeatable fashion, facilitating timely regulatory action. The purpose of this funding opportunity is to develop and test an AI- or ML-based algorithmic RWD model for post-market surveillance of complex generic drug products.
Eligibility
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Small businesses; City or township governments; Public housing authorities/Indian housing authorities; Private institutions of higher education; Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"; State governments; Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; County governments; Special district governments. Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →
More from this funder: 12 open opportunities from Food and Drug Administration (FDA).
Applying? Read how to write a winning grant proposal.
Data from Grants.gov, US federal government (public domain). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.